DGIdb - DACLIZUMAB Drug Record

DACLIZUMAB chembl:CHEMBL1201605 ApprovedImmunotherapy

Alternate Names:

ZINBRYTA
ZENAPAX
DACLIZUMAB
DACLIZUMAB BETA
RO-24-7375
IG GAMMA-1 CHAIN C REGION
ANTI-IL-2
HUMANIZED ANTICD25
drugbank:00111
rxcui:190353
chemidplus:152923-56-3
chembl:CHEMBL1201605

Drug Info:

Year of Approval	1997
Drug Class	immunosuppressive agents
FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	immunosuppressant
Drug Groups	withdrawn
Drug Categories	antibodies, monoclonal, humanized
Drug Categories	immunomodulatory agents
Drug Categories	interleukin 2 receptor-directed antibody interactions
Drug Categories	interleukin-2 receptor antagonist
Drug Categories	interleukin-2 receptor blocking antibody

(3 More Sources)

Publications:

Garcia et al., Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis., Transplant. Proc.
Monti et al., 2009, Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells., Am. J. Transplant.
Shamsi et al., 2005, Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report., J Pak Med Assoc
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Krouwels et al., 1996, Glucocorticosteroids affect functions of airway- and blood-derived human T-cell clones, favoring the Th1 profile through two mechanisms., Am. J. Respir. Cell Mol. Biol.
Przepiorka et al., 2000, Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease., Blood
Patlolla et al., 2007, Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation., Am. J. Transplant.
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Simms et al., 1991, Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function., J. Immunol.
Aguillón et al., 2003, [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]., Rev Med Chil
Burkhardt et al., 1989, Anti-IL-2 receptor monoclonal antibody AMT-13 increases soluble IL-2 receptor levels in vivo., Immunology
Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.
Light et al., 2002, Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation., Clin Transplant
Ramos et al., 1989, Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody., Transplantation
Galandrini et al., 1993, Antibodies to CD44 trigger effector functions of human T cell clones., J. Immunol.
Hoshino et al., 1991, Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders., Blood
Martelletti et al., 1990, Defective expression of IL-2 receptors on peripheral blood lymphocytes from patients with cluster headache., Headache
Hayakawa et al., 1991, The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone., J. Immunol.
Lanier et al., 1985, Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen)., J. Exp. Med.

DACLIZUMAB IL2RB

Interaction Score: 5.41

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
15022409 2647626 15814281 12372041 11752352 2571203

Sources:
DrugBank ChemblInteractions
DACLIZUMAB FCGR2C

Interaction Score: 3.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB C1R

Interaction Score: 2.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB C1QA

Interaction Score: 2.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB C1QB

Interaction Score: 2.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB C1QC

Interaction Score: 1.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB IL2RA

Interaction Score: 1.68

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Direct Interaction? True

PMIDs:
16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
DACLIZUMAB FCGR2B

Interaction Score: 1.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB FCGR2A

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB FCGR3B

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8097750 1835892 2335478 1900882 2415663

Sources:
DrugBank
DACLIZUMAB IL2RG

Interaction Score: 0.68

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DACLIZUMAB FCGR1A

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1828823

Sources:
DrugBank
DACLIZUMAB FCGR3A

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
DACLIZUMAB IL2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

DrugBank: DB00111

Version: 5.1.7

Alternate Names:

DACLIZUMAB DrugBank Drug Name

152923-56-3 CAS Number

Zenapax Drug Brand

Drug Info:

Drug Type biotech

Drug Groups investigational

Drug Groups withdrawn

Publications:

Aguillón et al., 2003, [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]., Rev Med Chil

Burkhardt et al., 1989, Anti-IL-2 receptor monoclonal antibody AMT-13 increases soluble IL-2 receptor levels in vivo., Immunology

Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.

TEND: DACLIZUMAB
- Version: 01-August-2011
Alternate Names:

DACLIZUMAB Primary Drug Name

Drug Info:

Drug Class immunosuppressive agents

Year of Approval 1997

Publications:
TdgClinicalTrial: DACLIZUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications immunosuppressant

Drug Class monoclonal antibody

FDA Approval approved

Publications:
GuideToPharmacology: 178103462
- Version: 29-September-2020
Alternate Names:

DACLIZUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Daclizumab
- Version: 2020.06.01
Alternate Names:

D0P1BZ TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201605
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201605
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Interleukin-2 receptor inhibitor
Direct Interaction	yes

DACLIZUMAB	DrugBank Drug Name
152923-56-3	CAS Number
Zenapax	Drug Brand

Drug Type	biotech
Drug Groups	investigational
Drug Groups	withdrawn

antibody (inhibitory)
inhibitor (inhibitory)

antibody (inhibitory)
inhibitor (inhibitory)

DACLIZUMAB Drug Record

DACLIZUMAB chembl:CHEMBL1201605 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes

PMIDs: 15022409 2647626 15814281 12372041 11752352 2571203

Sources: DrugBank ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes Direct Interaction? True

PMIDs: 16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8097750 1835892 2335478 1900882 2415663

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1828823

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

DrugBank: DB00111

Alternate Names: DACLIZUMAB DrugBank Drug Name 152923-56-3 CAS Number Zenapax Drug Brand

Drug Info: Drug Type biotech Drug Groups investigational Drug Groups withdrawn

TEND: DACLIZUMAB

Alternate Names: DACLIZUMAB Primary Drug Name

Drug Info: Drug Class immunosuppressive agents Year of Approval 1997

Publications:

TdgClinicalTrial: DACLIZUMAB

Alternate Names:

Drug Info: Drug Indications immunosuppressant Drug Class monoclonal antibody FDA Approval approved

Publications:

GuideToPharmacology: 178103462

Alternate Names: DACLIZUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Daclizumab

Alternate Names: D0P1BZ TTD Drug ID

Drug Info:

Publications:

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
15022409 2647626 15814281 12372041 11752352 2571203

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Direct Interaction? True

PMIDs:
16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
8097750 1835892 2335478 1900882 2415663

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
1828823

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Alternate Names:

DACLIZUMAB DrugBank Drug Name

152923-56-3 CAS Number

Zenapax Drug Brand

Drug Info:

Drug Type biotech

Drug Groups investigational

Drug Groups withdrawn

Alternate Names:

DACLIZUMAB Primary Drug Name

Drug Info:

Drug Class immunosuppressive agents

Year of Approval 1997

Drug Info:

Drug Indications immunosuppressant

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

DACLIZUMAB GuideToPharmacology Ligand Name

Alternate Names:

D0P1BZ TTD Drug ID